上海交大昂立股份有限公司 二○二五年五月 2024 年年度股东会 会议资料 现场会议时间：2025 年 5 月 20 日（星期二）下午 14:30 网络投票时间：采用上海证券交易所网络投票系统，通过交易系统投票平台的投票 时间为股东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 现场会议地点：上海市徐汇区田州路 99 号 13 号楼 11 楼大会议室 | 一、2024 | 年年度股东会会议议程············································1 | | --- | --- | | 二、2024 | 年年度股东会须知················································3 | | 三、审议本次股东会议案··················································4 | | | 1、2024 | 年度董事会工作报告································ ...

Core Viewpoint - The report highlights a black market in cross-border e-commerce health products, where domestic products are falsely labeled as imports, harming consumer rights and disrupting the market order. In contrast, Shanghai Jiao Tong University Angli Co., Ltd. (referred to as Angli) demonstrates growth and recovery in a trust-crisis industry by focusing on reliable branding and operational improvements [1][2]. Group 1: Company Performance - In 2024, Angli achieved an operating income of 325 million yuan, a year-on-year increase of 9.74%, and turned a profit with a net profit attributable to shareholders of 30.48 million yuan and a net profit after deducting non-recurring gains and losses of 5.82 million yuan [1]. - The company reported a net operating cash flow of 63.38 million yuan, reflecting a year-on-year growth of 14.12% [1]. - After years of losses from 2018 to 2022, Angli's financial situation improved significantly following a change in control in 2022, leading to a turnaround in profitability in 2023 and 2024 [2]. Group 2: Strategic Focus - Angli's strategy for 2024 emphasizes focusing on the health sector, ensuring stable operations, and enhancing product innovation, channel upgrades, and quality management [2][3]. - The company has restructured its health product segment to primarily focus on self-operated online sales, supported by special channel distributors and bulk procurement, resulting in steady sales growth [3]. - Angli has introduced new health products and improved existing ones, expanding its product line to include various health supplements [3]. Group 3: Market Position and Future Outlook - The health product industry is experiencing increased regulatory scrutiny, leading consumers to prefer reputable brands, which positions Angli favorably as it strengthens its market presence [3]. - Following the change in control, the new major shareholder has taken steps to stabilize ownership, including a 174 million yuan tender offer, increasing their stake to 30.06% [3]. - With a focus on operational efficiency and quality service in its healthcare segment, Angli's future prospects appear promising as it navigates the evolving market landscape [3].

Group 1 - The company plans to distribute a cash dividend of 0.118 yuan per 10 shares, totaling approximately 9.14 million yuan, which represents 30% of the net profit attributable to shareholders for the year 2024 [35][80][81] - The company achieved total revenue of 325 million yuan in 2024, with a net profit of 30.48 million yuan, marking a turnaround from previous losses [14][35] - The company operates in the health and wellness industry, which is experiencing significant growth, with the Chinese health market projected to grow from 10.2 trillion yuan in 2022 to 10.9 trillion yuan in 2023, at a compound annual growth rate of approximately 8.7% [2][3] Group 2 - The aging population and increasing health issues in China are driving the growth of the medical and elderly care industry, which is expected to reach a market size of 30 trillion yuan by 2035 [3][4] - The company’s main business segments include the research, production, and sales of health products, as well as the operation and management of elderly care institutions [4][11] - The company has introduced new health products in 2024, including various dietary supplements and functional foods, to meet diverse health needs [5][6][10] Group 3 - The company’s operational model includes both self-operated and consulting services for elderly care institutions, focusing on providing comprehensive health management and care services [11][12] - The company has established a diversified sales strategy, emphasizing online sales through e-commerce platforms and enhancing its presence on social media [9][10] - The company’s financial health is supported by a robust operational framework, with a focus on maintaining quality and compliance in its service offerings [64][70]

Group 1 - The company held the ninth supervisory board meeting on April 27, 2025, where the profit distribution plan for 2024 was approved with 5 votes in favor, 0 abstentions, and 0 against [1] - The supervisory board believes the profit distribution plan complies with relevant laws and regulations, and it does not harm the interests of shareholders [1] - The profit distribution plan will be submitted to the shareholders' meeting for approval [1] Group 2 - The company announced the confirmation of daily related party transactions for 2024 and the expected transactions for 2025, which are deemed necessary for normal business operations [4][5] - The daily related party transactions are conducted under principles of openness, fairness, and justice, ensuring no adverse impact on the company's operations or minority shareholders [4][6] - The company is involved in a lawsuit regarding unpaid consulting management fees, with an appeal filed after an unfavorable first-instance judgment [4][12] Group 3 - The company announced a change in accounting policy based on the Ministry of Finance's new regulations, which will not have a significant impact on financial results or shareholder interests [15][21] - The new accounting policy will be implemented from January 1, 2024, and does not require shareholder meeting approval [15][20] Group 4 - The company reported a total of 40,271,908.77 yuan in asset impairment provisions for 2024, which positively impacted the consolidated profit for the year [27] - The company conducted impairment tests on various assets and made provisions based on prudence [24][25] Group 5 - The company plans to provide guarantees for its wholly-owned subsidiaries, with a total guarantee amount not exceeding 40 million yuan [32][35] - The guarantee is intended to support the subsidiaries' operational funding needs and will be submitted for shareholder approval [34][36] - The company has no overdue guarantees and the proposed guarantees are considered manageable risks [33][44] Group 6 - The company will hold its 2024 annual shareholders' meeting on May 20, 2025, with both on-site and online voting options available [49][50] - The meeting will address various proposals that have been previously approved by the board and supervisory committee [52][53]

上海交大昂立股份有限公司 2024 年度独立董事述职报告 陆坚 作为上海交大昂立股份有限公司（以下简称"公司"）的独立董事，本人在2024年 度工作中，严格按照《公司法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第1号——规范运作》《上市公司独立董事管理办法》等法律、法 规和规范性文件，以及《公司章程》《独立董事工作制度》等公司规章和制度，凭借丰 富的专业知识和经验，积极参加公司董事会及各专门委员会会议、股东会，在董事会日 常工作及决策中尽职尽责，对董事会审议的重大事项发表了独立客观的意见，为董事会 的科学决策提供支撑，促进公司规范运作，本着对全体股东负责的态度，忠实、勤勉履 行独立董事职责。现将本人于2024年度工作情况作如下报告： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰富的 经验。本人个人工作履历、专业背景以及兼职情况如下： 本人陆坚，男，复旦大学临床医疗本科。农工民主党党员，杨浦区政协委员。现任 上海市杨浦区控江医院肛肠外科副主任医师，肛肠外科、内镜中心主任。上海市中西结 合大肠肛门病 ...

上海交大昂立股份有限公司 作为公司独立董事，本人不在公司兼任除董事会专门委员会委员外的其他职务,本 人及配偶、父母、子女、主要社会关系没有在公司及其附属企业任职，也没有在直接或 间接持有公司5%以上已发行股份的股东单位任职；没有为公司及其附属企业提供财务、 法律、管理咨询、技术咨询等有偿服务，也没有从公司及其主要股东单位或有利害关系 的机构取得未予披露的其他利益，不存在可能妨碍我进行独立客观判断的关系，亦不存 在《上海证券交易所上市公司自律监管指引第1号——规范运作》《上市公司独立董事 管理办法》等相关法律法规规定的影响独立性的情况。 （一）个人工作履历、专业背景及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰富的 经验。本人个人工作履历、专业背景以及兼职情况如下： 本人萧耀熙，男，加拿大滑铁卢大学数学学士，香港注册会计师，加拿大安省特许 专业会计师。本人具备丰富的会计专业知识和经验，自1996年6月至2023年5月，在德勤 中国和德勤亚太历任多个高级管理职位。本人曾在德勤亚太区任公司发展领导人，负责 推进亚太地区大量收购项目。在德勤中国任首席运营官兼副首席执行官、华东区主管合 ...

上海交大昂立股份有限公司 2024 年度财务决算与 2025 年度财务预算报告 上海交大昂立股份有限公司（以下简称"公司"）2024 年度财务决算已经山东 舜天信诚会计师事务所（特殊普通合伙）审计并出具了标准无保留意见审计报告。 现将财务决算情况报告如下： 重要且变动较大的资产项目说明如下： 一、重要财务决算数据和财务指标 1、营业总收入 3.25 亿元，同比涨幅 9.74%； 2、归属于母公司所有者的净利润为 3,048 万元，实现扭亏为盈； 3、每股收益 0.04 元，同比增加 0.09 元； 4、每股净资产 0.48 元，同比增加 0.04 元。 二、资产、负债与所有者权益 1、资产 截至 2024 年 12 月 31 日，公司总资产为 7.59 亿元，比年初减少 0.56 亿元，降 幅 6.90%。资产发生重大变化的有： | 项目名称 | 期末余额 | 期初余额 | 变动比例% | | --- | --- | --- | --- | | 长期股权投资 | 27,918,904.00 | 40,403,103.95 | -30.90 | 长期股权投资变动原因：公司于 2024 年 2 月与权益法公司上海 ...

公司代码：600530 公司简称：交大昂立 上海交大昂立股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业 内部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督 和专项监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性 进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披 露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层 负责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本 报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性 承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目 标提供合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循 的程度降 ...

上海交大昂立股份有限公司 关于会计师事务所 2024 年度履职情况的评估报告 上海交大昂立股份有限公司（以下简称"公司"）聘请山东舜天信诚会计师事务 所（特殊普通合伙）（以下简称"舜天信诚"）作为公司 2024 年度财务报告审计机构 及内部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司选 聘会计师事务所管理办法》，公司对舜天信诚 2024 年审计过程中的履职情况进行评估。 经评估，公司认为舜天信诚资质等方面合规有效，履职保持独立性，勤勉尽责，公允 表达意见，具体情况如下： 一、资质条件 山东舜天信诚会计师事务所成立于 2001 年，2020 年公司进行合伙制转制，转制后 的事务所名称为"山东舜天信诚会计师事务所（特殊普通合伙）"，注册地址：山东 省济南市历下区华能路 38 号汇源大厦 708 室，首席合伙人肖东义。2024 年度末合伙人 数量 17 人、注册会计师人数 144 人、签署过证券服务业务审计报告的注册会计师人数 15 人。2024 年度经审计的业务收入 6,146.57 万元，其中审计业务收入 4,722.99 万元， 证券业务收入 704.81 万元；2024 年挂牌公司审计 ...

上海交大昂立股份有限公司 2024 年，上海交大昂立股份有限公司（以下简称"公司"）董事会严格按照《公司 法》《证券法》以及《上海证券交易所股票上市规则》等法律法规及《公司章程》《股 东大会议事规则》《董事会议事规则》等公司制度的规定，本着对全体股东负责的态度， 恪尽职守、积极行使职权，认真履行股东会赋予的职责，贯彻执行股东会通过的各项决 议。全体董事勤勉尽责，积极推进董事会决议的实施，不断规范公司治理，保证公司持 续、稳定发展。 一、2024 年公司总体经营情况 2024 年，公司实现营业收入 32,518.19 万元，同比增长 9.74%；实现归属于上市公 司股东的净利润 3,048.14 万元，同比实现扭亏为盈；2024 年底，公司总资产为 75,887.95 万元，归属于上市公司股东的净资产为 32,571.10 万元。 二、2024 年公司董事会日常工作情况 （一）董事会组织召开股东会并执行股东会决议情况 报告期内，公司董事会召集并组织了 2 次股东会，会议召开情况如下： | 会议时间 | | | | 会议名称 | 审议的议案 审议通过了《公司 2023 年度董事会工作报告》《公司 2023 | | ...